{"id":2071,"date":"2026-07-23T06:01:00","date_gmt":"2026-07-22T21:01:00","guid":{"rendered":"http:\/\/project-sbi.local\/ir-news\/sbi%ec%9d%b8%eb%b2%a0-%ed%8f%ac%ed%8a%b8%ed%8f%b4%eb%a6%ac%ec%98%a4-%ec%a7%80%ed%88%ac%ec%a7%80%eb%b0%94%ec%9d%b4%ec%98%a4-%ed%95%9c%ea%b5%ad%ed%88%ac%ec%9e%90%ec%8b%a0%ed%83%81%ec%9a%b4%ec%9a%a9\/"},"modified":"2026-10-22T17:01:30","modified_gmt":"2026-10-22T08:01:30","slug":"sbi-investment-portfolio-company-g2gbio-selected-as-a-constituent-of-korea-inves","status":"publish","type":"ir","link":"https:\/\/sbi13.dayworks.kr\/en\/ir-news\/sbi-investment-portfolio-company-g2gbio-selected-as-a-constituent-of-korea-inves\/","title":{"rendered":"SBI Investment Portfolio Company G2GBIO Selected as a Constituent of Korea Investment Management&#8217;s New ETF \u2018ACE K-Bio KOSDAQ Active\u2019"},"content":{"rendered":"<ul>\n<li>G2GBIO, an SBI Investment portfolio company and long-acting drug delivery system (DDS) platform company, has been selected as a constituent of \u2018ACE K-Bio KOSDAQ Active,\u2019 a new ETF listed by Korea Investment Management on July 21.<\/li>\n<li>The ETF focuses on KOSDAQ-listed biotechs specializing in technology licensing (license-out). G2GBIO was included in the obesity treatment category together with D&amp;D Pharmatech, alongside leading biotechs such as Alteogen, LigaChem Biosciences, Voronoi and Oscotec.<\/li>\n<li>As competition intensifies in the global obesity treatment market to develop long-acting formulations that extend dosing intervals, this shows that G2GBIO&#039;s platform technology is also viewed by capital markets as a promising candidate for technology licensing.<\/li>\n<\/ul>\n<p>The full article is available at the link below.<\/p>\n<p><a href=\"https:\/\/www.thebell.co.kr\/front\/newsview.asp?click=F&#038;key=202607200924214880108662\" target=\"_blank\" rel=\"noopener\">https:\/\/www.thebell.co.kr\/front\/newsview.asp?click=F&amp;key=202607200924214880108662<\/a><\/p>\n","protected":false},"featured_media":0,"template":"","ir_type":[40],"class_list":["post-2071","ir","type-ir","status-publish","hentry","ir_type-news-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/sbi13.dayworks.kr\/en\/wp-json\/wp\/v2\/ir\/2071","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sbi13.dayworks.kr\/en\/wp-json\/wp\/v2\/ir"}],"about":[{"href":"https:\/\/sbi13.dayworks.kr\/en\/wp-json\/wp\/v2\/types\/ir"}],"wp:attachment":[{"href":"https:\/\/sbi13.dayworks.kr\/en\/wp-json\/wp\/v2\/media?parent=2071"}],"wp:term":[{"taxonomy":"ir_type","embeddable":true,"href":"https:\/\/sbi13.dayworks.kr\/en\/wp-json\/wp\/v2\/ir_type?post=2071"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}